C0111208||cytotoxic T-lymphocyte antigen 4
C0006826||cancers
C1955832||systematic review
C0920317||meta-analysis
C0543472||outcomes
C0936012||analyzing
C0111208||CTLA-4
C0006826||cancers
C0920317||meta-analysis
C0111208||CTLA-4
C0006826||cancer
C0023866||literature
C1138432||PubMed
C0282574||EMBASE
C0282574||Web of Science
C0282574||Cochrane Library
C0030667||clinicopathological features
C0936012||analyzed
C0282574||Stata version 12.0 software
C0111208||CTLA-4
C0027651||tumors
C1515021||subgroup
C0936012||analyses
C0871738||experimental methods
C0111208||CTLA-4
C0038951||survey
C0111208||CTLA-4
C0752046||SNP
C1515021||subgroup
C1515021||subgroups
C0936012||analyzing
C0032520||PCR
C0016263||flow cytometry
C0936012||analysis
C0111208||CTLA-4+
C0003323||CD4+
C0024264||lymphocytes
C0111208||CTLA-4+
C0003323||CD4+
C0024264||lymphocytes
C0111208||CTLA-4+
C0085358||CD8+
C0024264||lymphocytes
C0111208||CTLA-4+
C0085358||CD8+
C0024264||lymphocytes
C0111208||CTLA-4
C3854082||prognosis
C0087111||therapeutic strategies
C0006826||cancer